公开(公告)号：US20150258189A1

公开(公告)日：2015-09-17

申请号：US14432076

申请日：2013-09-27

Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY ,  TORAY INDUSTRIES, INC. ,  TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE ,  UNIVERSITY OF INDONESIA ,  INDONESIAN INSTITUTE OF SCIENCES (LIPI)

Inventor： Hak Hotta ,  Chie Aoki ,  Takaji Wakita ,  Soedarmono Pratiwi ,  Sitompul Ratna ,  Hakim Lukman ,  Kardono Leonardus

IPC: A61K39/29 ,  C12N7/00 ,  G01N33/50 ,  C07D309/10

CPC classification number: A61K39/29 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K35/66 ,  A61K2039/5252 ,  C07D309/10 ,  C12N7/00 ,  C12N2770/24251 ,  C12N2770/28034 ,  C12N2770/28051 ,  C12N2770/28061 ,  C12Q1/18 ,  G01N33/5014 ,  G01N2333/186 ,  G01N2500/04 ,  G01N2500/10 ,  A61K2300/00

Abstract: A HCV particle formation promoter is capable of promoting formation of HCV particles in culture cells, and a method enhances production of HCV particles. A method evaluates an anti-HCV agent candidate substance, and a method produces a HCV vaccine. The HCV particle formation promoter includes as an active ingredient a statin or a pharmaceutically acceptable salt thereof. Addition of the statin or pharmaceutically acceptable salt thereof to HCV-infected culture cells can promote formation of infectious HCV particles and enhance production of the particles. In addition, an anti-HCV agent candidate substance is evaluated by culturing HCV-infected cells in the presence of the HCV particle formation promoter and the anti-HCV agent candidate substance. Further, a HCV vaccine is produced by using HCV particles produced by the method of enhancing production of HCV particles.

Abstract translation: HCV颗粒形成促进剂能够促进培养细胞中HCV颗粒的形成，并且该方法增强HCV颗粒的产生。 一种方法评估抗HCV药物候选物质，并且方法产生HCV疫苗。 HCV颗粒形成促进剂包括他汀类或其药学上可接受的盐作为活性成分。 向HCV感染的培养细胞中加入他汀类药物或其药学上可接受的盐可以促进感染性HCV颗粒的形成并增强颗粒的产生。 此外，通过在HCV颗粒形成促进剂和抗HCV剂候选物质的存在下培养HCV感染细胞来评价抗HCV剂候选物质。 此外，通过使用通过增强HCV颗粒的产生的方法产生的HCV颗粒来生产HCV疫苗。